Live Analyst Rating Changes 8803 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Charles Pitman CFA
BARC
Charles Pitman CFA
Barclays
Wall Street Analyst
★★★☆☆
#954
on 13Foresight · ranked by our own returns
75%
Success Rate
+10.6%
Average Return
3 of 4 calls profitable · -3.2% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 75% of Charles Pitman CFA's ratings turned a profit when each position was held for 1 year — averaging +10.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

90 Buy 27 Hold 4 Sell
Charles's Stock Coverage 20 ratings · 2026-07-16
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
DE:BAYN
Bayer
 Jul 14, 2026 BUY Strong Buy
+9.3% avg upside
28 analysts
$60.00
26.19% Upside
 ·
DE:MRK
Merck KGaA
 Jun 26, 2026 HOLD Buy
-2.9% avg upside
33 analysts
$135.00
3.63% Downside
 ·
FR:BIM
bioMerieux
 Jun 23, 2026 HOLD Buy
+38.8% avg upside
12 analysts
$80.00
11.38% Upside
 ·
CH:LONN
Lonza Group Ltd
 Jun 22, 2026 BUY Strong Buy
+10.9% avg upside
20 analysts
$670.00
15.28% Upside
 ·
CH:PPGN
PolyPeptide Group AG
 Jun 16, 2026 BUY Buy
-25.5% avg upside
3 analysts
$40.00
14.72% Downside
 ·
GB:0NZT
UCB SA
 Jun 12, 2026 HOLD Buy
-3.7% avg upside
19 analysts
$300.00
28.85% Upside
 ·
CH:BANB
Bachem Holding AG
 Jun 09, 2026 HOLD Sell
-1.0% avg upside
4 analysts
$70.00
5.41% Downside
 ·
FR:DIM
Sartorius Stedim Biotech
 Apr 23, 2026 BUY Strong Buy
+32.4% avg upside
11 analysts
$220.00
16.47% Upside
 ·
DE:SRT3
Sartorius
 Apr 23, 2026 BUY Buy
+11.4% avg upside
18 analysts
$270.00
9.20% Upside
 ·
ES:GRF
Grifols
 Apr 22, 2026 BUY Buy
+64.3% avg upside
12 analysts
$12.50
38.57% Upside
 ·
CH:SDZ
Sandoz Group Ltd
 Mar 11, 2026 HOLD Buy
+2.5% avg upside
11 analysts
$75.00
15.70% Upside
 ·
IT:REC
Recordati Industria Chimica e Farmaceutica SPA
 Feb 12, 2026 HOLD Hold
-6.4% avg upside
7 analysts
$48.00
6.42% Downside
 ·
IT:DIA
DiaSorin S.p.A.
 Jan 06, 2026 SELL Hold
+55.6% avg upside
10 analysts
$60.00
13.57% Downside
 ·
GB:DIA
Dialight
 Jan 06, 2026 SELL Strong Sell
1 analyst
 — ·
BAYRY
Bayer
 Jan 06, 2026 BUY Buy
+202.6% avg upside
9 analysts
 — +30.3%
GB:0QW0
arGEN X
 Oct 31, 2025 BUY Strong Buy
-20.5% avg upside
24 analysts
$850.00
12.27% Upside
 ·
FR:IPN
Ipsen
 Oct 24, 2025 HOLD Buy
-22.8% avg upside
17 analysts
$125.00
22.24% Downside
 ·
ARGX
Argenx Se
 Apr 28, 2025 BUY Strong Buy
-12.9% avg upside
46 analysts
$743.25
13.90% Downside
 +24.8%
GRFS
Grifols SA
 Jan 04, 2024 BUY Buy
+252.5% avg upside
12 analysts
$20.58
185.50% Upside
 -32.1%
ABBV
AbbVie
 Jan 13, 2022 BUY Strong Buy
-3.7% avg upside
46 analysts
 — +19.4%
🔒 15 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Charles Pitman CFA — Frequently Asked Questions
How accurate are Charles Pitman CFA's stock ratings?
Based on the calls 13Foresight could measure, about 75% of Charles's ratings were profitable over a one-year hold, with an average return of +10.6% per rating, or -3.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Charles ranked on 13Foresight?
Charles Pitman CFA is currently ranked #954 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Charles cover?
Charles most recently has ratings on DE:BAYN, DE:MRK, FR:BIM, CH:LONN, CH:PPGN, GB:0NZT, CH:BANB, FR:DIM, DE:SRT3, ES:GRF, CH:SDZ, IT:REC and 8 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.